Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FIRST: Dr Reddys...

    FIRST: Dr Reddys unveils generic version of Hemabate injection indicated for abortion

    Farhat NasimWritten by Farhat Nasim Published On 2019-07-03T15:30:03+05:30  |  Updated On 3 July 2019 3:30 PM IST
    FIRST: Dr Reddys unveils generic version of Hemabate injection indicated for abortion

    The product is a generic version of Pfizer's Hemabate injection in the strength of 250 mcg/mL, it added.


    NEW DELHI: Dr Reddy's Laboratories Wednesday said it has launched in the US generic Carboprost Tromethamine injection used for aborting pregnancy.


    The company has launched Carboprost Tromethamine injection USP, 250 mcg/mL (1mL) single-dose vial in the US market, the pharma major said in a filing to BSE.


    The product is a generic version of Pfizer's Hemabate injection in the strength of 250 mcg/mL, it added.


    Also Read: Aurobindo Pharma, Dr Reddys, Torrent Pharma, Mylan cannot sell generic Gilenya patented by Novartis


    "We are pleased to be first-to-market with this product that has been designated as a Competitive Generic Therapy (CGT) by the FDA," Dr Reddy's Laboratories North America Generics CEO Marc Kikuchi said.


    With a CGT designation, the company has 180-day CGT exclusivity to market this product, he added.


    As per IQVIA Health data, Hemabate injection, 250 mcg/mL brand had US sales of approximately USD 55 million MAT for the twelve months ended April 2019, Dr Reddy's Labs said.


    Also Read: Dr Reddys unveils generic version of Vitamin K1 injection in US

    abortionabortion drugCarboprost Tromethamine injectionDr Reddy'sDr Reddy's LaboratoriesDr Reddy's LabsDRLgenericHemabateInjectionPfizerpharmapharma newspharma news indiapregnancyUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok